Heart Failure

EZR-201 combines an angiotensin receptor blocker, valsartan, with Rubireten delivery technology for the treatment of hypertension and heart failure.

The FDA has accepted the new drug application (NDA) for EZR-201, an investigational product from Ezra Innovations for the treatment of hypertension and heart failure.

In this clip, Dr. Peter Salgo, a professor of medicine and anesthesiology at Columbia University College of Physicians and Surgeons; and an associate director of Surgical Intensive Care at New York-Presbyterian Hospital discusses heart failure.

The costs of generic heart failure medications can vary by hundreds of dollars.

Treatment with Entresto was associated with a reduction in hospitalization and death up to 24% in patients with heart failure.

An initiative that lowered copays for prescription drugs also lowered hospitalizations by 40%

Type 2 diabetes patients struggle with high blood glucose levels that can damage nerves and blood vessels, factors that could trigger heart attacks.

Low health literacy, financial instability, and lack of social support promote poor adherence.

Poor medication adherence contributes to 125,000 deaths annually, causes up to half of all treatment failures, and costs the US healthcare system $100 billion each year.

Heart failure patients are much more likely to have diabetes than the general population.

The incidence of heart failure is increasing as the world's population ages and the rates of other, often comorbid, diseases (eg, diabetes, heart disease, obesity) increase.

This article summarizes recent literature surrounding the use of tolvaptan for acute heart failure.

That is, are they all equally effective?

The toxicity of cancer drugs increasingly causing cardiovascular complications in patients.

No difference found in mortality and cardiac events among patients that were and were not taking beta-blockers after an angioplasty.

Supplemental coenzyme Q10 may be a management option for patients with heart failure.

The FDA has approved Silvergate Pharmaceuticals' Qbrelis, the first lisinopril oral solution.

Heart failure with preserved ejection typically accompanied by hypertension, diabetes, lung disease, or chronic renal failure.

Top news of the day from across the health care landscape.

This article highlights the latest literature surrounding both new and old heart failure therapies.

Approximately 12.3% of patients diagnosed with heart failure were diagnosed with cancer.

Common drugs such as metformin or anesthesia could potentially cause complications for patients with heart failure.

Approximately 38% of women who had initial echocardiograms received a follow-up scan.

The American Heart Association has released a scientific statement cautioning against the use of some common drugs and supplements in patients with heart failure.

Depression affects 10% to 40% of patients with heart failure, depending on disease severity.

The Absorb GT1 Bioresorbable Vascular Scaffold System is the first coronary artery disease stent designed to be absorbed by the body.

Two new analyses have further cemented Entresto's place in heart failure therapy.

Approximately 24 to 25% of patients with type 2 diabetes and heart failure died within 18 months.

Patients with heart failure who have had 3 or more vaccines had a 55% decreased risk of developing dementia.

Fee-for-Service Medicare beneficiaries with heart failure accounted for 55.3% of readmissions.